Prediction of major bleeding events for patients with dual antiplatelet therapy after myocardial infarction—a validation of the PRECISE-DAPT cancer score

作者：Sacharias von Koch, Mamas A. Mamas, Mohamed Dafaalla, Francesco Costa, Sasha Koul, Tomas Jernberg, David Erlinge, Moman A. Mohammad · 发表于：European Heart Journal Open · 年份：2025 · DOI：10.1093/ehjopen/oeaf137 · 被引用次数：4 · 研究领域：Antiplatelet Therapy and Cardiovascular Diseases、Acute Myocardial Infarction Research、Atrial Fibrillation Management and Outcomes

The simplified original PRECISE-DAPT score was developed to identify patients at high bleeding risk (HBR) by using the following variables: age, haemoglobin, creatinine clearance and prior haemorrhage.1 A recent article in the European Heart Journal by Dafaalla et al. found that including cancer as a binary variable in the PRECISE-DAPT improve its discrimination ability.2 However, the score has not been validated using an external validation cohort. The objective of this study was to validate the PRECISE-DAPT cancer score using the Swedish Registry of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). RIKS-HIA contains data on all patient treated at a cardiac intensive care unit in Sweden and collects extensive information on e.g. patient characteristics, medications, and procedural characteristics. With deterministic linkage using personal identification numbers, RIKS-HIA was merged with the Swedish national patient registry to collect data on cancer status. The data underlying this article cannot be shared publicly due to patients’ privacy laws. The data were provided by the Uppsala Clinical Research Center and, upon a reasonable request, other researchers can access data through this institution. For this study, RIKS-HIA was used to identify all patients discharged with dual antiplatelet therapy (DAPT) after presenting with NSTEMI or STEMI between 30th June 2010 and 30th June 2020. Patients with missing values in the variables used to calcu...